FREMONT, Calif., Dec. 2, 2019 /PRNewswire/ -- Ardelyx, Inc.
(NASDAQ: ARDX), a specialized biopharmaceutical company focused on
developing first-in-class medicines to improve treatment for people
with cardiorenal diseases, announced that it will hold a conference
call tomorrow, December 3, at
8:00 am Eastern Time to review the
results from the pivotal Phase 3 PHREEDOM study evaluating
tenapanor in chronic kidney disease (CKD) patients on dialysis.
Tenapanor is Ardelyx's investigational, first-in-class, small
molecule, non-binder, phosphate absorption inhibitor.
To participate in the conference call, please dial (855)
296-9612 (domestic) or (920) 663-6277 (international) and refer to
conference ID 8065608. Live audio of the conference call and
accompanying slides will be simultaneously webcast and will be
available under the Investors section of the company's website at
www.ardelyx.com. The webcast will be archived and available
for replay for 60 days following the call.
About Ardelyx, Inc.
Ardelyx is focused on enhancing the way people with cardiorenal
diseases are treated by developing first-in-class medicines.
Ardelyx's cardiorenal pipeline includes tenapanor, a treatment of
hyperphosphatemia in people with end-stage renal disease (ESRD) who
are on dialysis, and RDX013, a potassium secretagogue program for
the potential treatment of high potassium, or hyperkalemia, a
problem among certain patients with kidney and/or heart disease. In
addition, Ardelyx has received approval of IBSRELA (tenapanor). To
efficiently bring its treatments to market, Ardelyx is pursuing
strategic collaborations for tenapanor for IBS-C and
hyperphosphatemia in certain territories. Ardelyx has established
agreements with Kyowa Kirin (formerly known as Kyowa Hakko Kirin)
in Japan, Fosun Pharma in
China and Knight Therapeutics in
Canada. For more information,
please visit http://www.ardelyx.com and connect with us on Twitter
@Ardelyx.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ardelyx-to-host-conference-call-on-december-3-to-review-results-from-the-pivotal-phase-3-phreedom-study-300967673.html
SOURCE Ardelyx